A detailed history of Daiwa Securities Group Inc. transactions in Replimune Group, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 200 shares of REPL stock, worth $2,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 200 -0.0%
Holding current value
$2,280
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

BUY
$17.09 - $27.91 $683 - $1,116
40 Added 25.0%
200 $5,000
Q3 2021

Nov 05, 2021

BUY
$28.98 - $39.54 $2,144 - $2,925
74 Added 86.05%
160 $5,000
Q4 2020

Feb 04, 2021

BUY
$23.5 - $52.65 $2,021 - $4,527
86 New
86 $3,000
Q4 2019

Jan 31, 2020

SELL
$11.61 - $17.21 $2,333 - $3,459
-201 Closed
0 $0
Q1 2019

Apr 26, 2019

SELL
$10.26 - $16.24 $1,528 - $2,419
-149 Reduced 42.57%
201 $3,000
Q4 2018

Feb 05, 2019

BUY
$9.97 - $15.57 $3,489 - $5,449
350 New
350 $4,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $562M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.